The Company enters 2026 with Multiple Phase 2 Catalysts collectively representing ~$8 billion in potential market ...
To sum up, GH001 has shown us pretty robust efficacy, a strong safety profile, and durable antidepressant effects. Going into ...
The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...
As 2026 begins, a slate of high-stakes clinical readouts—from a pivotal study of Novartis’ cardiovascular candidate ...
Traditional trial start-up workflows often follow a sequential path, from feasibility to contracting, then regulatory ...
Innovation in ophthalmology is often measured by what reaches the clinic—but the path to those breakthroughs begins much ...
After a lengthy downturn, the biotech industry finally gathered momentum in 2025. Key readouts in obesity, infectious disease ...
In a 10-year propensity-matched cohort study, Irene Tan, MD, of the Einstein Healthcare Network and Jefferson Health in ...
A structured data ownership model—rooted in ICH GCP principles, supported by MHRA and FDA interpretations, and documented in validated system specifications—will enable sponsors to maintain compliance ...
Rezdiffra FDA approval fuels sales; expansion to F4 MASH cirrhosis with 2027 trial data. Read more about MDGL stock here.
5d
Language Scientific Highlights the Role of Clinical Trial Translation Services in Patient Engagement
December 31, 2025 – PRESSADVANTAGE – Language Scientific, a life-science focused translation and localization provider, is drawing attention to the central role that clinical trial translation ...
Alzheimer’s disease blood test developer Quanterix put forward new clinical data from its Simoa assay, which it described as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback